Capella BioScience Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Capella BioScience General Information

Description

Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics for oncology and autoimmune disease, enabling researchers to research the latest medical technology-based drugs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Corporate Office
  • 158-160 North Gower Street
  • London NW1 2ND
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Capella BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 16-Feb-2021 000.00 Completed Clinical Trials - General
4. Later Stage VC 24-Sep-2020 00.00 000.00 0000 Completed Clinical Trials - General
3. Later Stage VC 16-Aug-2019 00.00 000.00 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) 03-Apr-2016 $15.7M $18.1M Completed Pre-Clinical Trials
1. Seed Round 22-Dec-2014 $2.35M $2.35M Completed Startup
To view Capella BioScience’s complete valuation and funding history, request access »

Capella BioScience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Shares 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preference 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Shares 2,171,715 $0.001306 $2.59 $2.59 1x $2.59 1.73%
Seed 1,500,000 $0.001306 $1.31 $1.31 1x $1.31 17.12%
To view Capella BioScience’s complete cap table history, request access »

Capella BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mA
Drug Discovery
London, United Kingdom
3 As of 2020
000.00
000000&0 000.00

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non p
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00

000000

e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ull
0000 000000000
Lebanon, NH
000 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Capella BioScience Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
Adimab Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
Kineta Formerly VC-backed Seattle, WA 00 00000 000000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

Capella BioScience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Capella BioScience Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Farzad Nazem Angel (individual) Minority 000 0000 000000 0
Index Ventures Venture Capital Minority 000 0000 000000 0
Lux Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Capella BioScience FAQs

  • When was Capella BioScience founded?

    Capella BioScience was founded in 2014.

  • Who is the founder of Capella BioScience?

    Steve Holmes Ph.D is the founder of Capella BioScience.

  • Where is Capella BioScience headquartered?

    Capella BioScience is headquartered in London, United Kingdom.

  • What is the size of Capella BioScience?

    Capella BioScience has 3 total employees.

  • What industry is Capella BioScience in?

    Capella BioScience’s primary industry is Drug Discovery.

  • Is Capella BioScience a private or public company?

    Capella BioScience is a Private company.

  • What is Capella BioScience’s current revenue?

    The current revenue for Capella BioScience is 000000.

  • How much funding has Capella BioScience raised over time?

    Capella BioScience has raised $37.7M.

  • Who are Capella BioScience’s investors?

    Advent Life Sciences, DCVC, Farzad Nazem, Index Ventures, and Lux Capital are 5 of 7 investors who have invested in Capella BioScience.

  • Who are Capella BioScience’s competitors?

    Centrose, Adimab, NexImmune, TScan Therapeutics, and Kineta are some of the 47 competitors of Capella BioScience.

  • When was Capella BioScience acquired?

    Capella BioScience was acquired on 16-Feb-2021.

  • Who acquired Capella BioScience?

    Capella BioScience was acquired by Centessa Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »